Oxysterol-binding protein family I is the target of minor enviroxime-like compounds

Journal of Virology

Volumn 87, Issue 8, 2013, Pages 4252-4260

  Arita, Minetaro ^a   Kojima, Hirotatsu ^b   Nagano, Tetsuo ^b   Okabe, Takayoshi ^b   Wakita, Takaji ^a   Shimizu, Hiroyuki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYCHOLESTEROL; 3 (3,4 DIMETHOXYPHENYL) 2,5 DIMETHYL N [2 (4 MORPHOLINYL)ETHYL]PYRAZOLO[1,5 A]PYRIMIDIN 7 AMINE; 3BETA,17BETA 16,16 DIMETHYL 3 [(TETRAHYDRO 2H PYRAN 2 YL)OXY]ANDROST 5 EN 17 OL; ANTIVIRUS AGENT; BINDING PROTEIN; ENVIROXIME; OXYSTEROL BINDING PROTEIN FAMILY 2; OXYSTEROL BINDING PROTEIN FAMILY I; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; PROTEIN SCAP; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN; T 00127HEV1; T 00127HEV2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; EMBRYO; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE REPRESSION; GENE SILENCING; GOLGI COMPLEX; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL LINE; HUMANS; PICORNAVIRIDAE; RECEPTORS, STEROID;

EID: 84875776334     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03546-12     Document Type: Article

References (68)

1. Bodian D. 1949. Histopathologic basis of clinical findings in poliomyelitis. Am. J. Med. 6:563-578.
2. Couderc T, Christodoulou C, Kopecka H, Marsden S, Taffs LF, Crainic R, Horaud F. 1989. Molecular pathogenesis of neural lesions induced by poliovirus type 1. J. Gen. Virol. 70:2907-2918.
3. Salk JE, Bazeley PL, Bennett BL, Krech U, Lewis LJ, Ward EN, Youngner JS. 1954. Studies in human subjects on active immunization against poliomyelitis. II. A practical means for inducing and maintaining antibody formation. Am. J. Public Health Nations Health 44:994-1009.
4. Sabin AB. 1965. Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA 194:872-876.
5. Collett MS, Neyts J, Modlin JF. 2008. A case for developing antiviral drugs against polio. Antiviral Res. 79:179-187.
6. Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication NRC. 2006. Exploring the role of antiviral drugs in the eradication of polio: workshop report. National Academies Press, Washington, DC.
7. Fox MP, Otto MJ, McKinlay MA. 1986. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob. Agents Chemother. 30:110-116.
8. Pevear DC, Fancher MJ, Felock PJ, Rossmann MG, Miller MS, Diana G, Treasurywala AM, McKinlay MA, Dutko FJ. 1989. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J. Virol. 63:2002-2007.
9. Molla A, Hellen CU, Wimmer E. 1993. Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors. J. Virol. 67:4688-4695.
10. Caliguiri LA, Tamm I. 1968. Action of guanidine on the replication of poliovirus RNA. Virology 35:408-417.
11. Eggers HJ, Tamm I. 1961. Spectrum and characteristics of the virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole. J. Exp. Med. 113:657-682.
12. Shimizu H, Agoh M, Agoh Y, Yoshida H, Yoshii K, Yoneyama T, Hagiwara A, Miyamura T. 2000. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J. Virol. 74:4146-4154.
13. De Palma AM, Heggermont W, Lanke K, Coutard B, Bergmann M, Monforte AM, Canard B, De Clercq E, Chimirri A, Purstinger G, Rohayem J, van Kuppeveld F, Neyts J. 2008. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J. Virol. 82:4720-4730.
14. Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 43:2444-2450.
15. De Palma AM, Purstinger G, Wimmer E, Patick AK, Andries K, Rombaut B, De Clercq E, Neyts J. 2008. Potential use of antiviral agents in polio eradication. Emerg. Infect. Dis. 14:545-551.
16. Rodriguez PL, Carrasco L. 1992. Gliotoxin: inhibitor of poliovirus RNA synthesis that blocks the viral RNA polymerase 3Dpol. J. Virol. 66:1971-1976.
17. Bordeleau ME, Mori A, Oberer M, Lindqvist L, Chard LS, Higa T, Belsham GJ, Wagner G, Tanaka J, Pelletier J. 2006. Functional characterization of IRESes by an inhibitor of theRNAhelicase eIF4A. Nat. Chem. Biol. 2:213-220.
18. Irurzun A, Perez L, Carrasco L. 1992. Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A. Virology 191:166-175.
19. Maynell LA, Kirkegaard K, Klymkowsky MW. 1992. Inhibition of poliovirus RNA synthesis by brefeldin A. J. Virol. 66:1985-1994.
20. Hsu NY, Ilnytska O, Belov G, Santiana M, Chen YH, Takvorian PM, Pau C, van der Schaar H, Kaushik-Basu N, Balla T, Cameron CE, Ehrenfeld E, van Kuppeveld FJ, Altan-Bonnet N. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799-811.
21. Wikel JH, Paget CJ, DeLong DC, Nelson JD, Wu CY, Paschal JW, Dinner A, Templeton RJ, Chaney MO, Jones ND, Chamberlin JW. 1980. Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl] methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidaz ol-2-amine. Inhibitors of rhinovirus multiplication. J. Med. Chem. 23:368-372.
22. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2011. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J. Virol. 85:2364-2372.
23. Delang L, Paeshuyse J, Neyts J. 2012. The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. Biochem. Pharmacol. 84:1400-1408.
24. Belov GA, Feng Q, Nikovics K, Jackson CL, Ehrenfeld E. 2008. A critical role of a cellular membrane traffic protein in poliovirus RNA replication. PLoS Pathog. 4:e1000216. doi:10.1371/journal.ppat.1000216.
25. Cuconati A, Molla A, Wimmer E. 1998. Brefeldin A inhibits cell-free, de novo synthesis of poliovirus. J. Virol. 72:6456-6464.
26. Heinz BA, Vance LM. 1995. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 69:4189-4197.
27. Brown-Augsburger P, Vance LM, Malcolm SK, Hsiung H, Smith DP, Heinz BA. 1999. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex. Arch. Virol. 144:1569-1585.
28. Buontempo PJ, Cox S, Wright-Minogue J, DeMartino JL, Skelton AM, Ferrari E, Albin R, Rozhon EJ, Girijavallabhan V, Modlin JF, O'Connell JF. 1997. SCH 48973: a potent, broad-spectrum, antienterovirus compound. Antimicrob. Agents Chemother. 41:1220-1225.
29. Oberste MS, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS. 2009. In vitro antiviral activity of V-073 against polioviruses. Antimicrob. Agents Chemother. 53:4501-4503.
30. Kouiavskaia DV, Dragunsky EM, Liu HM, Oberste MS, Collett MS, Chumakov KM. 2011. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073. Antivir. Ther. 16:999-1004.
31. Kouiavskaia D, Collett MS, Dragunsky EM, Sarafanov A, ChumakovKM. 2011. Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice. Clin. Vaccine Immunol. 18:1387-1390.
32. Liu HM, Roberts JA, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS, Oberste MS. 2012. Characterization of poliovirus variants selected for resistance to the antiviral compound v-073. Antimicrob. Agents Chemother. 56:5568-5574.
33. De Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Altel T, De Clercq E, van Kuppeveld F, Neyts J. 2009. Mutations in the non-structural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 53:1850-1857.
34. Arita M, Wakita T, Shimizu H. 2008. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J. Gen. Virol. 89:2518-2530.
35. Arita M, Wakita T, Shimizu H. 2009. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J. Gen. Virol. 90:1869-1879.
36. Arita M, Takebe Y, Wakita T, Shimizu H. 2010. A bifunctional antienterovirus compound that inhibits replication and early stage of enterovirus 71 infection. J. Gen. Virol. 91:2734-2744.
37. Ulferts R, van der Linden L, Lanke KH, Thibaut HJ, Neyts J, van Kuppeveld FJ. 2012. New lead drug candidates for the treatment of enterovirus infections. abstr P-110. EUROPIC 2012, XVII Meeting of the European Study Group on the Molecular Biology of Picornaviruses, Saint Raphael, France, 3 to 7 June 2012.
38. Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G. 2009. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. U. S. A. 106:7577-7582.
39. Vaillancourt FH, Brault M, Pilote L, Uyttersprot N, Gaillard ET, Stoltz JH, Knight BL, Pantages L, McFarland M, Breitfelder S, Chiu TT, Mahrouche L, Faucher AM, Cartier M, Cordingley MG, Bethell RC, Jiang H, White PW, Kukolj G. 2012. Evaluation of phosphatidylinositol- 4-kinase IIIalpha as a hepatitis C virus drug target. J. Virol. 86:11595-11607.
40. Arita M, Nagata N, Sata T, Miyamura T, Shimizu H. 2006. Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J. Gen. Virol. 87:3317-3327.
41. Baltera RF Jr, Tershak DR. 1989. Guanidine-resistant mutants of poliovirus have distinct mutations in peptide 2C. J. Virol. 63:4441-4444.
42. Crotty S, Saleh MC, Gitlin L, Beske O, Andino R. 2004. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein. J. Virol. 78:3378-3386.
43. Kawano M, Kumagai K, Nishijima M, Hanada K. 2006. Efficient trafficking of ceramide from the endoplasmic reticulum to the Golgi apparatus requires a VAMP-associated protein-interacting FFAT motif of CERT. J. Biol. Chem. 281:30279-30288.
44. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
45. Sasaki J, Ishikawa K, Arita M, Taniguchi K. 2012. ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sites. EMBO J. 31:754-766.
46. Lehto M, Olkkonen VM. 2003. The OSBP-related proteins: a novel protein family involved in vesicle transport, cellular lipid metabolism, and cell signalling. Biochim. Biophys. Acta 1631:1-11.
47. Dawson PA, Van der Westhuyzen DR, Goldstein JL, Brown MS. 1989. Purification of oxysterol binding protein from hamster liver cytosol. J. Biol. Chem. 264:9046-9052.
48. Ridgway ND, Dawson PA, Ho YK, Brown MS, Goldstein JL. 1992. Translocation of oxysterol binding protein to Golgi apparatus triggered by ligand binding. J. Cell Biol. 116:307-319.
49. Hanada K, Kumagai K, Yasuda S, Miura Y, Kawano M, Fukasawa M, Nishijima M. 2003. Molecular machinery for non-vesicular trafficking of ceramide. Nature 426:803-809.
50. Horton JD, Goldstein JL, Brown MS. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109:1125-1131.
51. Nishimura T, Inoue T, Shibata N, Sekine A, Takabe W, Noguchi N, Arai H. 2005. Inhibition of cholesterol biosynthesis by 25- hydroxycholesterol is independent of OSBP. Genes Cells 10:793-801.
52. van der Schaar HM, van der Linden L, Lanke KH, Strating JR, Purstinger G, de Vries E, de Haan CA, Neyts J, van Kuppeveld FJ. 2012. Coxsackievirus mutants that can bypass host factor PI4KIIIbeta and the need for high levels of PI4P lipids for replication. Cell Res. 22:1576-1592.
53. Kandutsch AA, Shown EP. 1981. Assay of oxysterol-binding protein in a mouse fibroblast, cell-free system. Dissociation constant and other properties of the system. J. Biol. Chem. 256:13068-13073.
54. Ridgway ND. 2010. Oxysterol-binding proteins. Subcell. Biochem. 51: 159-182.
55. Amako Y, Sarkeshik A, Hotta H, Yates J, III, Siddiqui A. 2009. Role of oxysterol binding protein in hepatitis C virus infection. J. Virol. 83:9237-9246.
56. Amako Y, Syed GH, Siddiqui A. 2011. Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol- binding protein and ceramide transfer protein. J. Biol. Chem. 286: 11265-11274.
57. Beh CT, Cool L, Phillips J, Rine J. 2001. Overlapping functions of the yeast oxysterol-binding protein homologues. Genetics 157:1117-1140.
58. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV. 2002. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 99:15669-15674.
59. Pezacki JP, Sagan SM, Tonary AM, Rouleau Y, Belanger S, Supekova L, Su AI. 2009. Transcriptional profiling of the effects of 25- hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus. BMC Chem. Biol. 9:2.
60. Sagan SM, Rouleau Y, Leggiadro C, Supekova L, Schultz PG, Su AI, Pezacki JP. 2006. The influence of cholesterol and lipid metabolism on host cell structure and hepatitis C virus replication. Biochem. Cell Biol. 84:67-79.
61. Schaffer FL, Gordon M. 1966. Differential inhibitory effects of actinomycin D among strains of poliovirus. J. Bacteriol. 91:2309-2316.
62. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Buhler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. 2011. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32-45.
63. Berger KL, Kelly SM, Jordan TX, Tartell MA, Randall G. 2011. Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J. Virol. 85:8870-8883.
64. Godi A, Pertile P, Meyers R, Marra P, Di Tullio G, Iurisci C, Luini A, Corda D, De Matteis MA. 1999. ARF mediates recruitment of PtdIns- 4-OH kinase-beta and stimulates synthesis of PtdIns(4,5)P2 on the Golgi complex. Nat. Cell Biol. 1:280-287.
65. Banerji S, Ngo M, Lane CF, Robinson CA, Minogue S, Ridgway ND. 2010. Oxysterol binding protein-dependent activation of sphingomyelin synthesis in the Golgi apparatus requires phosphatidylinositol 4-kinase IIalpha. Mol. Biol. Cell 21:4141-4150.
66. Stefan CJ, Manford AG, Baird D, Yamada-Hanff J, Mao Y, Emr SD. 2011. Osh proteins regulate phosphoinositide metabolism at ER-plasma membrane contact sites. Cell 144:389-401.
67. de Saint-Jean M, Delfosse V, Douguet D, Chicanne G, Payrastre B, Bourguet W, Antonny B, Drin G. 2011. Osh4p exchanges sterols for phosphatidylinositol 4-phosphate between lipid bilayers. J. Cell Biol. 195: 965-978.
68. Goto A, Liu X, Robinson CA, Ridgway ND. 2012. Multisite phosphorylation of oxysterol-binding protein regulates sterol binding and activation of sphingomyelin synthesis. Mol. Biol. Cell 23:3624-3635.